Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk

 
• By Jessica Merrill, Joseph Haas, and Sten Stovall

Stakeholders are eager for details on the Takeda/Shire merger and on what Trump said to Pfizer CEO Ian Read to cause the recent about-face on price increases. Other key topics will be status updates on Teva's Copaxone franchise and on Novo Nordisk's oral semaglutide.

Q2 written on a speechbubble

More from Business

More from Scrip